Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Abstract Backgrounds Tamoxifen is typically used to treat patients with estrogen receptor alpha (ERα)-positive breast cancer. However, 30% of these patients gain acquired resistance to tamoxifen during or after tamoxifen treatment. As a Ras modulator, Nogo-B receptor (NgBR) is required for tumorigen...
Main Authors: | Pin Gao, Xiang Wang, Ying Jin, Wenquan Hu, Yajun Duan, Aiping Shi, Ye Du, Dong Song, Ming Yang, Sijie Li, Bing Han, Gang Zhao, Hongquan Zhang, Zhimin Fan, Qing Robert Miao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-018-1028-5 |
Similar Items
-
Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice
by: Zhi Zhang, et al.
Published: (2021-03-01) -
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
by: Anja Kathrin Wege, et al.
Published: (2018-11-01) -
Regulation of estrogen receptor alpha expression by translation or degradation and the relevance to tamoxifen resistance in breastcancer
by: Gong, Chun, et al.
Published: (2013) -
Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions
by: Shih-Ying Wu, et al.
Published: (2021-03-01) -
Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system
by: Julia J Segura-Uribe, et al.
Published: (2017-01-01)